DUBLIN, May 10, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/xrtmp7/global) has announced the addition of the "Global Biosimilars Market 2014-2018" report to their offering. 

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. 

The report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc. Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. 

Key Topics Covered: 

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
05. Introduction
06. Market Landscape
07. Market Segmentation by Application
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
17. Patent Expiries
18. Key Vendor Analysis
19. Other Reports in this Series

Companies Mentioned: 

• 3SBio Inc.
• Actavis plc
• Amgen Inc.
• AstraZeneca plc
• Baxter International Inc.
• Biocon Ltd.
• Biogen Idec Inc.
• Bioton S.A.
• Boehringer Ingelheim GmbH
• Celltrion Inc.
• Cipla Ltd.
• Coherus Biosciences Inc.
• Daiichi Sankyo Co. Ltd.
• Dr. Reddy's Laboratories Ltd.
• Emcure Pharmaceuticals Ltd.
• F. Hoffmann-La Roche Ltd.
• GE Healthcare Ltd.
• GeneScience Pharmaceuticals Co. Ltd.
• GlaxoSmithKline plc
• Hospira Inc.
• Intas Pharmaceuticals Ltd.
• JCR Pharmaceuticals Co. Ltd.
• LG Life Sciences Co. Ltd.
• Merck & Co. Inc.
• Mylan Inc.
• Novartis AG
• Pfizer Inc.
• Ranbaxy Laboratories Ltd.
• Samsung Biologics Co. Ltd.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Wockhardt Ltd.
• iBio Inc.

For more information visit http://www.researchandmarkets.com/research/xrtmp7/global

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets